The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma

The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma

Systemic inflammation is a hallmark of cancer, and it has a pivotal role in hepatocellular carcinoma (HCC) development and progression. We conducted a retrospective study including 362 patients receiving immune check-point inhibitors (ICIs) across three continents, evaluating the influence of neutro...

Full description

Bibliographic Details
Main Authors: Ambreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri, Matthias Pinter, Lorenz Balcar, Bernhard Scheiner, Thomas U. Marron, Tomi Jun, Anwaar Saeed, Hannah Hildebrand, Mahvish Muzaffar, Musharraf Navaid, Abdul Rafeh Naqash, Anuhya Gampa, Umut Ozbek, Junk-Yi Lin, Ylenia Perone, Bruno Vincenzi, Marianna Silletta, Anjana Pillai, Yinghong Wang, Uqba Khan, Yi-Hsiang Huang, Dominik Bettinger, Yehia I. Abugabal, Ahmed Kaseb, Tiziana Pressiani, Nicola Personeni, Lorenza Rimassa, Naoshi Nishida, Luca Di Tommaso, Masatoshi Kudo, Arndt Vogel, Francesco A. Mauri, Alessio Cortellini, Rohini Sharma, Antonio D’Alessio, Celina Ang, David J. Pinato
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Cancers
Subjects:
hepatocellular carcinoma
inflammatory biomarkers
neutrophil-lymphocyte ratio
platelet-lymphocyte ratio
prognostic nutritional index
Online Access:https://www.mdpi.com/2072-6694/14/1/186

Internet

https://www.mdpi.com/2072-6694/14/1/186

Similar Items